This trial will test a new combination drug treatment for people with advanced solid tumors or brain tumors. Researchers will track how well the treatment works and how safe it is.
2 Primary · 3 Secondary · Reporting Duration: At 8 weeks after first treatment; up to 14 months for cohort
35 Total Participants · 1 Treatment Group
Primary Treatment: ivosidenib and nivolumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: